These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 1865968

  • 41. Effects of parathyroid hormone and calcitonin on osteoclast formation in vitro.
    Feldman RS, Krieger NS, Tashjian AH.
    Endocrinology; 1980 Oct; 107(4):1137-43. PubMed ID: 7408763
    [Abstract] [Full Text] [Related]

  • 42. Quantitative bone histology in end-stage renal failure.
    Evans RA, Flynn J, Dunstan CR, George CR.
    Prog Biochem Pharmacol; 1980 Oct; 17():236-41. PubMed ID: 7208502
    [Abstract] [Full Text] [Related]

  • 43. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.
    Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M.
    Am J Kidney Dis; 2002 Mar; 39(3):525-32. PubMed ID: 11877571
    [Abstract] [Full Text] [Related]

  • 44. Evolution of parathyroid hormone and calcitonin plasma levels during haemodialysis and following renal transplantation.
    Fuss M, Geurts J, Dupont E, Corvilain J.
    Acta Clin Belg; 1978 Mar; 33(1):16-22. PubMed ID: 358714
    [No Abstract] [Full Text] [Related]

  • 45. Calcium and phosphorus metabolism in maintenance hemodialysis.
    Ritz E, Mehls O, Krempien B.
    Adv Nephrol Necker Hosp; 1980 Mar; 9():71-108. PubMed ID: 6773320
    [No Abstract] [Full Text] [Related]

  • 46. Arterial calcifications and bone histomorphometry in end-stage renal disease.
    London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC.
    J Am Soc Nephrol; 2004 Jul; 15(7):1943-51. PubMed ID: 15213285
    [Abstract] [Full Text] [Related]

  • 47. Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis.
    Niccoli P, Brunet P, Roubicek C, Roux F, Baudin E, Lejeune PJ, Berland Y, Conte-Devolx B.
    Eur J Endocrinol; 1995 Jan; 132(1):75-81. PubMed ID: 7850012
    [Abstract] [Full Text] [Related]

  • 48. Skeletal status in adolescents with end-stage renal failure: a longitudinal study.
    Pluskiewicz W, Adamczyk P, Drozdzowska B, Szprynger K, Szczepańska M, Halaba Z, Karasek D.
    Osteoporos Int; 2005 Mar; 16(3):289-95. PubMed ID: 15221204
    [Abstract] [Full Text] [Related]

  • 49. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H, Baradaran A.
    J Ayub Med Coll Abbottabad; 2004 Mar; 16(2):3-8. PubMed ID: 15455608
    [Abstract] [Full Text] [Related]

  • 50. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
    Henley C, Yang Y, Davis J, Lu JY, Morony S, Fan W, Florio M, Sun B, Shatzen E, Pretorius JK, Richards WG, St Jean DJ, Fotsch C, Reagan JD.
    J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
    [Abstract] [Full Text] [Related]

  • 51. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series.
    Amerling R, Harbord NB, Pullman J, Feinfeld DA.
    Blood Purif; 2010 Jun; 29(3):293-9. PubMed ID: 20090316
    [Abstract] [Full Text] [Related]

  • 52. Calcitropic hormonal status in north Indian patients with end-stage renal disease.
    Singh AK, Avula S, Kher V, Rao DS, Mithal A.
    Natl Med J India; 1999 Jun; 12(5):202-7. PubMed ID: 10612998
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I, Balon BP, Rus I, Marc J.
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [Abstract] [Full Text] [Related]

  • 55. [Serum osteocalcin in children with chronic renal insufficiency].
    Peco-Antić A, Nastić-Mirić D, Milikić V, Babić D, Pejcić I, Kostić M, Paripović V, Jovanović O, Kruscić D, Mancić J.
    Srp Arh Celok Lek; 1996 Mar; 124(9-10):227-31. PubMed ID: 9102853
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Mineral metabolism in infants with malignant osteopetrosis: heterogeneity in plasma 1,25-dihydroxyvitamin D levels and bone histology.
    Cournot G, Trubert-Thil CL, Petrovic M, Boyle A, Cormier C, Girault D, Fischer A, Garabedian M.
    J Bone Miner Res; 1992 Jan; 7(1):1-10. PubMed ID: 1549952
    [Abstract] [Full Text] [Related]

  • 58. The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus.
    Dunstan CR, Hills E, Norman AW, Bishop JE, Mayer E, Wong SY, Johnson JR, George CR, Collett P, Kalowski S.
    Q J Med; 1985 May; 55(217):127-44. PubMed ID: 4001311
    [Abstract] [Full Text] [Related]

  • 59. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
    Bucciante G, Bernardi A, Biasia F, Milan G, Donato D.
    Minerva Med; 1985 Mar 10; 76(9-10):415-7. PubMed ID: 3982698
    [No Abstract] [Full Text] [Related]

  • 60. The effect of endogenous parathyroid hormone in iliac bone structure and turnover in healthy postmenopausal women.
    Rao DS, Parikh N, Palnitkar S, Qiu S.
    Calcif Tissue Int; 2013 Sep 10; 93(3):288-95. PubMed ID: 23842963
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.